Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Stem Cells. 2014 Apr;32(4):844–851. doi: 10.1002/stem.1597

Figure 1. Implementation of personalized strategies to target leukemia stem cells in AML.

Figure 1

Current technological advances will allow for tailored therapeutic approaches based on a full characterization of AML tumors. Genomic squencing, transcriptional profiling, flow cytometry and metabolomic assays (e.g. evaluation for IDH1/IDH2 mutations, stem cell immunophenotype, mitochondrial mass, mitochondrial priming) will allow for a classification of patients and better identification of actionable therapeutic targets.